Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Two Japanese drug companies to set up new plants in the US
by Aayushi Pratap
June 24, 2024
| A version of this story appeared in
Volume 102, Issue 19
Kyowa Kirin says it will spend up to $530 million to build a biomanufacturing facility in Sanford, North Carolina. The 16,000 m2 site, set to open in 2027, will make antibodies and other biologic therapies for Kyowa Kirin and third parties. Meanwhile, Asahi Kasei Medical subsidiary Bionova Scientific, a biologics contract production firm, will establish a facility in The Woodlands, Texas, to make plasmid DNA, a key ingredient in cell and gene therapies and in messenger RNA–based vaccines.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X